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ORIGINAL ARTICLE
Knowledge, attitudes and experience associated with testing 
for prostate cancer: a comparison between male doctors and 
men in the community
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D. HILL1
1The Cancer Council Victoria,*  2Department of Human Services, Melbourne, Victoria and 3Department of Surgery, 
Monash University, Melbourne, Victoria, Australia
Abstract
Background: Debate about testing for prostate cancer
using prostate-specific antigen (PSA) and digital rectal
examination (DRE) continues. The evidence of
benefit from screening for prostate cancer using PSA
tests is inconclusive, and it is unclear how PSA can be
used most effectively in the detection of prostate
cancer. Given the lack of consensus, it is important
that consumers understand the issues in a way that will
permit them to decide whether or not to have a test
and, if symptomatic, how their condition is managed.
Aims: To compare prostate cancer knowledge, atti-
tudes and testing experiences reported by male
doctors and men in the community, despite the lack
of evidence of a benefit.
Methods: The primary method for ascertaining the
attitudes of male doctors (MD) was a telephone
survey, with some doctors electing to complete a
written survey. Each MD was selected, at random,
from a register of male practitioners aged ≥ 49 years
of age. A total of 266 MD participated in the survey.
The community sample (CS) was accessed using a
telephone survey. Five hundred male Victorian resi-
dents aged ≥ 49 years of age participated in the study.
Results: 
Knowledge – Overall, 55% of the CS indicated
correctly that prostate disease is sometimes cancer,
compared to 83% of MD.
Attitudes – Fifty-five per cent of MD believed men
should be tested for prostate disease at least every
2 years, compared to 68% of men in the CS.
Testing experience – Forty-five per cent of MD
had been tested for prostate cancer in the past, and
92% of those tests were reported as negative. In the
CS, 56% had been tested for prostate cancer in the
past, and 78% of the results were reported as nega-
tive. The significant independent predictors of having
had a prostate test among MD were: (i) age
(≥ 60 years; odds ratio (OR): 1.59; 95% confidence
intervals (CI): 1.30–1.88) and (ii) positive attitudes
towards regular testing for prostate cancer (OR: 2.27;
95% CI: 1.98–2.56). The significant independent
predictors for the CS were: (i) age (≥ 60 years;
OR: 1.65; 95% CI: 1.40–1.89), (ii) being married
(OR: 1.30; 95% CI: 1.00–1.60), (iii) knowledge that
prostate disease was sometimes cancer (OR: 1.46; 95%
CI: 1.26–1.66) and (iv) positive attitudes towards
regular testing for prostate cancer (OR: 2.12; 95%
CI: 1.90–2.34).
Conclusions: The results highlight that testing for
prostate cancer is widespread in the community and
in the medical profession. Further research should be
undertaken to identify how to help men make fully
informed decisions about prostate cancer testing.
(Intern Med J 2002; 32: 215–223)
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INTRODUCTION
Prostate cancer is a significant public health issue.
The reported incidence of prostate cancer doubled
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between 1985 and 1994 with the introduction of
more intensive medical surveillance using prostate
specific antigen (PSA) and other tests.1
Debate about testing for prostate cancer using PSA
and digital rectal examination (DRE) continues.2,3
The majority of evidence-based reviews indicate that
evidence of benefit from screening for prostate cancer
using PSA testing is inconclusive.4,5 This doubt is
expected to remain for the next 5 to 10 years.4,5 It is
also unclear how PSA can be most effectively used in
the detection of prostate cancer.2 However, large
population-based studies have shown increased
survival benefits in the early treatment of prostate
cancer when compared with no active therapy in men
with moderately and poorly differentiated disease.6
The Australian Health Technology Advisory
Committee (AHTAC)1 recommends that men
without symptoms should not be screened for
prostate cancer due to a lack of positive evidence
about the efficacy of the tests and treatments for
prostate cancer. Men who are offered, or who request
a PSA or similar test should be fully informed of its
limitations. In addition, consumers should be aware
of their potential involvement in further diagnostic
and treatment choices resulting from the testing
process.1
Given the lack of consensus on prostate cancer
testing, it is particularly important that consumers
understand the issues in a way that will permit them
to decide whether or not to have a PSA test or, if
symptomatic, how their condition is managed. It is
evident that men who simply follow professional
advice could be managed in vastly different ways,
depending upon which doctor they consult. The
AHTAC recommended that men being offered or
requesting a PSA test must be fully informed of the
limitations of the available tests and of the possible
further diagnostic and treatment choices they may
face if they decide to proceed with an initial test.1
High levels of prostate cancer testing occur in the
Australian community. In 1996, costs of $A10
million were incurred by fees charged for PSA and
prostatic acid phosphatase tests.7,8 This could be
attributed to tests for men with symptoms or for
monitoring patients with prostate cancer who have
undergone therapy. Alternatively, it could be attrib-
uted to requests for prostate cancer tests from
members of the asymptomatic population, who may
not be fully informed of the speculative and contro-
versial nature of the test and may not have an
awareness of treatment options and their effective-
ness.9 In the absence of overwhelming evidence in
favour of regular testing for prostate cancer, there are
also short-term economic disincentives to do so.10
The aim of this research was to assess the attitudes
and testing experiences associated with prostate
cancer testing among male doctors (MD) who had
reached an age at which they themselves were at risk
of prostate cancer, and to compare their views with
those of a sample of men in the community in the
same age group. MD were selected as the comparison
group as they are presumed to be well-informed
health consumers and, as a result, their attitudes,
practices and personal experience with prostate
cancer testing could be a good indicator of what an
informed population might think and do.
METHODS
Male doctors (MD)
A survey was conducted on 266 (62%) MD, gener-
ated from a random selection of 430 male
practitioners aged between 49 and 71 years who were
contactable from the Medical Register of Victoria.
The survey was conducted over a 4-week period
between April and May 1997. Twenty pilot interviews
were conducted to pre-test the survey. The primary
method was telephone surveying, although some
doctors elected to complete a written survey. Tele-
phone numbers were obtained from White Pages
OnLine (Telstra Corporation, Australia). Up to eight
callbacks were attempted in order to maximize partic-
ipation. Five experienced interviewers conducted
telephone interviews, which averaged 5–10 min in
duration. The main reasons for non-participation
were: (i) no response to repeated telephone calls to
the practice (43%), (ii) retired (13%), (iii) too busy
(13%) or (iv) overseas (9%).
Approximately one-third of the MD approached
stated that they would only complete the survey if it
were in a written format. In an attempt to keep the
response rate at an acceptable level, these doctors
were offered the option of completing a written
version of the questionnaire. The telephone survey
was adapted into a self-completion format. To
optimize participation, many of the open-ended ques-
tions that were included in the telephone survey were
omitted. Both the mail and telephone surveys covered
five main subject areas: (i) sources of knowledge on
prostate cancer, (ii) attitudes towards prostate cancer
testing, (iii) whether tested for prostate cancer,
(iv) professional practice with prostate cancer testing
and (v) recall on urinary symptoms experienced.
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Of the 112 surveys sent out, 69 (61%) were
completed and returned. A minimum of two follow
ups was made to inquire about non-returns. No
significant differences on the variables age, marital
status and area of work were found between those
who responded by telephone (n = 197) and those who
completed the mail survey (n = 69). The two groups
were therefore collapsed for analysis.
Community sample (CS)
The sample was generated through a random selec-
tion of telephone numbers from White Pages OnLine
for the state of Victoria. A total of 3529 telephone
numbers were dialled to obtain a final sample of 500
(47% participation rate) men who met the selection
criteria (i.e. were aged ≥ 49 years of age and were
English speaking (n = 1057)). No information was
collected on non-respondents, consequently selection
bias could not be ascertained.
Twenty-four pilot interviews were conducted to pre-
test the survey questionnaire. The main survey was
conducted over a 3-week period between January and
February 1997.
Ethics
Ethics approval was received from the Anti-Cancer
Council of Victoria and all respondents gave informed
consent to participate in the survey.
Sample size and statistical analyses
To derive a more precise indication of knowledge and
attitudes among men, the CS was over-sampled
compared to the doctor’s survey.
Data collected from the survey were analysed using
SPSS (Statistical Package for the Social Sciences,
SPSS Statistical Algorithms, SPSS Inc., Chicago, IL,
USA). Descriptive statistics were used to characterize
the sample. Statistical tests for univariate analyses
included χ2 tests for comparing groups and t-tests for
comparing means. A logistic regression model was
constructed to determine the independent predictors
of having had a test for prostate cancer and included:
(i) age, (ii) area of specialty (in the doctor’s survey
only, general practitioner (GP) vs other specialty),
(iii) marital status and (iv) education level attained
(in the CS only, primary, secondary or tertiary).
Cognitive features were also included in the model,
and comprised knowledge and attitudes associated
with prostate cancer testing. The results of the
analyses were considered statistically significant when
P < 0.05.
RESULTS
The demographic characteristics of the MD who
participated are shown in Table 1. GPs represented
the largest specialty (42%), followed by surgery
Table 1 Demographic characteristics of respondents
Demographic characteristic % of community sample
n = 500
% of male doctors
n = 266
Age*
< 60 years 41 62
≥ 60 years 59 38
Education
Primary 17 –
Secondary 53 –
Tertiary or higher degree 30 100
Marital status
Married 86 93
Separated/divorced 7 5
Widowed 4 1
Never married 3 1
Employment status
Full-time employed 39 89
Part-time employed 7 7
Unemployed 3 –
Retired/pensioned 51 4
* Missing data in male doctor survey.
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(16%), internal medicine (4%), urology (3%) and
rehabilitation (3%). The CS was skewed towards the
older age groups, with men ≥ 60 years of age
accounting for 59% of respondents (as opposed to
38% of MD). In addition, respondents were generally
well educated (30% having completed a tertiary
degree or higher) and 86% were married.
Knowledge of prostate issues
Overall, 55% of the CS, compared with 83% of MD,
indicated correctly that prostate disease is ‘sometimes’
cancer (Table 2). By contrast, just over one-quarter
(27%) of the CS thought it was ‘mostly’ or ‘always’
cancer, compared to 1% of MD.
Both groups were asked their opinion on the general
accuracy of prostate cancer tests for the detection
of prostate cancer. Sixty-four per cent of MD indi-
cated that tests were ‘quite accurate’, which was the
statement we considered to be the most appropriate
response. This figure compared to 40% in the CS
(χ2 = 13.92; degrees of freedom (d.f.) = 1; P < 0.001).
A significant number of people in the CS (40%)
replied ‘unsure/can’t say’ on the accuracy of the tests,
compared to 10% of MD. Community respondents
who believed tests to be ‘quite’ or ‘very’ accurate were
significantly more likely to have been tested for
prostate cancer themselves (χ2 = 13.28; d.f. = 1;
P < 0.001). MD who believed the tests to be ‘quite’
or ‘very’ accurate were not more likely to be tested
for prostate cancer themselves (χ2 = 1.44; d.f. = 1;
P = 0.23). Significantly more older men (aged
≥ 60 years) in the CS (68%) believed prostate tests to
be ‘quite’ or ‘very’ accurate, compared to 57% of
MD in the same age group (χ2 = 5.16; d.f. = 1;
P = 0.02).
Attitudes towards prostate cancer testing
Both groups were asked, ‘How often do you think
men of your age should have a prostate cancer test?’
Overall, 55% of MD believed men should be tested at
least every 2 years, compared to 68% of men in the
CS (χ2 = 11.23; d.f. = 1; P < 0.001).
Men ≥ 60 years of age in the CS were significantly
more likely to specify the need for regular testing
(71%), compared to 58% of MD in the same age
group (χ2 = 7.39; d.f. = 1; P < 0.001). No differences
were found in the < 60 years age group.
Men in both samples who had been tested previously
were more likely to be supportive of men being tested
every 2 years or less (CS 83% vs MD 75%; χ2 = 13.2;
d.f. = 5; P < 0.02). MD who had been tested for
prostate cancer were significantly more likely to
Table 2 Comparison of responses between community sample and male doctors
Questions Community sample
%
Male doctors
%
Knowledge n = 482* n = 266
Is prostate disease
Always cancer 4 –
Mostly cancer 23 1
Sometimes cancer 55 83
Rarely cancer 5 16
Can’t say 13 –
Accuracy of the prostate cancer test n = 500 n = 252*
Very 17 8
Quite 40 64
Inaccurate/quite 2 14
Unsure/can’t say 40 10
Depends on test 1 4
Attitudes
How often should men of your age have a prostate test? n = 500 n = 262*
≤ 2 years 68 55
3 years 5 8
5 years or less – 2
Only with symptoms 18 28
Never 1 2
Can’t say 8 3
*Missing data.
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believe that men should be tested for prostate cancer
on a regular basis (χ2 = 7.19; d.f. = 1; P < 0.05).
Testing experience: male doctors
Forty-five per cent of MD had been tested for
prostate cancer in the past. Of that group, 56% had a
PSA test by itself and 36% had a PSA in combination
with a DRE (Fig. 1). The likelihood of having had a
test varied with age (χ2 = 28.40; d.f. = 4; P < 0.001),
with the highest percentage (77%) in the 65–69 year
age group. The majority of tests (67%) had been
performed in the previous 12 months and this
percentage was high across all age groups. Overall,
92% of the tests were negative.
A logistic regression model was constructed to deter-
mine the independent predictors of ever having had a
test for prostate cancer and included: (i) age, (ii) area
of specialty (GP vs other specialist) and (iii) marital
status. Cognitive features were also included in the
model and comprised  knowledge and attitudes asso-
ciated with prostate cancer testing. The significant
independent predictors of having had a prostate test
were: (i) age (≥ 60 years; OR 1.59; 95% CI
1.30–1.88) and (ii) positive attitudes towards prostate
cancer testing every 2 years (OR 2.27; 95% CI
1.98–2.56) (Table 3).
Testing experience: community sample
In the CS, 279 respondents (56%) had been tested for
prostate cancer in the past (Fig. 1). Of these, 23% had
a PSA alone, 39% reported to have had a DRE alone
and 37% were a combination of PSA and DRE.
Seventy-eight per cent of the results were reported as
negative and 64% of tests were performed by GPs.
Having had a test varied with age (χ2 = 22.75; d.f. = 4;
P < 0.001), with the highest proportion (67%) in the
65–69 years of age group. The majority of tests (68%)
had been performed in the last 12 months and this
proportion was high across all age groups.
To assess the independent predictors of having had a
test for prostate cancer, a logistic regression model was
constructed, including: (i) age, (ii) marital status and
(iii) education level attained (primary, secondary or
tertiary) (Table 3). The significant predictors for the
CS were: (i) age (≥ 60 years; OR: 1.65; 95% CI:
1.40–1.89), (ii) being married (OR: 1.30; 95% CI:
1.00–1.60), (iii) knowledge that prostate disease was
‘sometimes’ cancer (OR: 1.46; 95% CI: 1.26–1.66) and
(iv) positive attitudes towards prostate cancer testing at
least every 2 years (OR: 2.12; 95% CI: 1.90–2.34).
One-third of MD who had experienced a prostate test,
compared with 29% of men in the CS, reported being
Table 3 The association between patients who have had a test for prostate cancer, sociodemographic characteristics and 
cognitive features
Variable Community sample Male doctors
n OR
(95% CI)
n OR
(95% CI)
Age
< 60 years 108 1.65 104 1.59
≥ 60 years 374 (1.40–1.89) 143 (1.30–1.88)
Marital status
Married 418 1.30 230 1.11
Other 64 (1.00–1.60) 17 (0.56–1.66)
Area of specialty
GP – – 104 1.09
Other specialist – – 143 (0.46–1.72)
Knowledge
Prostate disease is 
Sometimes cancer 275 1.46 206 1.15
Other response 207 (1.26–1.66) 41 (0.78–1.52)
Quite accurate 196 1.16 166 1.10
Other response 286 (0.95–1.37) 81 (0.80–1.40)
Attitudes
How often should men have test?
≤ 2 years 329 2.12 136 2.27
Other 153 (1.90–2.34) 111 (1.98–2.56)
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Figure 1 Comparison of testing experience among community sample and male doctors. *missing data;  **does not add up 
to 100% because of multiple responses. DRE, digital rectal examination; PSA, prostate specific antigen; TRUS, transrectal 
ultrasound.
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‘somewhat’ or ‘very’ worried while waiting for their
results (Fig. 1). This difference was not significant. Of
those tested, over 80% of respondents in both groups
reported that they were tested regularly (Fig. 1). The
main reasons why men in the CS were having tests
included: (i) ‘just to keep a check on it’ (50%),
(ii) because they were in the right age group (11%) and
(iii) follow up after a positive result (16%). Similarly,
the main reasons reported by the MD were (i) to keep
a check on it (50%), (ii) to follow up a positive result
(16%) and (iii) being in the right age group (11%).
Overall, 147 (55%) of MD (46% aged ≥ 60 years)
indicated they had never been tested for prostate
cancer, compared to 221 (44%) in the  CS (39% aged
≥ 60 years). The major reasons that men did not have
tests were: (i) they were not experiencing any
symptoms of prostate disorder (MD 34%; CS 53%),
(ii) they had not got around to it (MD 20%; CS
14.5%), (iii) controversy over the tests (MD 33%)
and (iv) no particular reason (CS 11%).
Male doctors were compared with their colleagues
who had never been tested. Those who had been
tested at least once were significantly more likely:
(i) to believe that men should be tested for prostate
cancer on a regular basis (χ2 = 9.39; d.f. = 1;
P < 0.01), (ii) to believe that all men over 50 years of
age should be screened for prostate cancer (χ2 = 23.3;
d.f. = 1; P < 0.01) and (iii) to be over the age of 55
(χ2 = 9.26; d.f. = 1; P < 0.01).
Information provided and received
Overall, 30% of doctors who conduct prostate cancer
tests reported that they use educational resources to
assist their discussions with patients. Just over one-
third (35%) of the CS reported that they were told of
the limitations of the test, and 55% reported that they
were given an adequate explanation prior to the test
(Fig. 1). Nearly two-thirds (65%) of CS respondents
indicated that they were informed of their results
personally by their doctor and 22% indicated that the
doctor advised them over the telephone. The
remaining 13% were informed through a variety of
methods (i.e. by the doctor’s receptionist or by letter)
or were told they would only be contacted if there was
a positive result.
Perceived messages about prostate cancer testing
Both groups were asked to identify what was the main
message they had read, seen or heard on prostate
cancer testing. MD reported that: (i) the test was
controversial (24%), (ii) there was a need for men to
have regular tests (18%), (iii) there was a query over
the accuracy of the test (14%), (iv) early checking is
important (12%), (v) they were unsure of relevance
(11%) and (vi) there was confusion over screening
(8%). CS indicated that: (i) there was a need for men
to be tested regularly (52%), (ii) there was a need to
have a test if symptomatic (17%), (iii) early checking
is important (10%) and (iv) it is important to be
aware of prostate disease (9%).
DISCUSSION
This study was undertaken to identify information
that could enhance a public health campaign
designed to address the issue of prostate cancer
testing in the community. To our knowledge, no
other study has compared a medical and a community
group regarding their knowledge, attitudes and expe-
rience associated with prostate cancer testing.
In discussing these results, it is important to recognize
the potential limitations of this research. Self-report
measures can result in bias due to social desirability
and, in the case of reported behaviours, selective
recall. Consequently, the results must be interpreted
with this in mind. Due to the goals and sampling
frame, the results may not represent all medical
practitioners who conduct or refer patients for
prostate cancer tests. However, as the respondents
were randomly selected and with the response rate
achieved, we are confident that the respondents’
answers were a reflection of attitudes and behaviours
of MD. With regard to the CS, no information was
collected on non-respondents, consequently selection
bias could not be ascertained. However, given that
the respondents were generally well educated and the
majority were married, we are aware of potential bias
in the sample.
Although there is no officially endorsed prostate
cancer-testing programme in Australia, testing was
prevalent in the community. Approximately 55% of
men aged 50–70 years in Victoria have had at least
one test for prostate cancer, which is consistent with
other studies.5,11,12
The study revealed that men in the CS had a general
awareness about prostate cancer without possessing
detailed information. Men who held positive attitudes
about prostate cancer testing were more likely to have
been tested for prostate cancer. In addition, men who
had knowledge about prostate disease were more
likely to have been tested. Only 30% of doctors
reported using educational resources to explain
prostate cancer testing and only one-third of the CS
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reported that their medical practitioner explained the
limitations of the test to them.
In terms of understanding what factors influenced
MD to be tested, the results suggested that there were
more complex factors than simply whether MD
understood the facts about prostate cancer testing.
The medical practitioners surveyed in the study
demonstrated that variable knowledge levels and
different approaches to testing were also prevalent. As
a group of relatively well-informed consumers, MD
provided a range of reasons for being tested, which
included: (i) a desire for reassurance, (ii) ‘being in the
right age group’ and (iii) ‘being a sensible thing to
do’. This suggests that underlying attitudes about
prostate cancer (such as perceived personal vulnera-
bility to prostate cancer and survival benefit if the
disease is detected and treated at an early stage) may
influence their decisions on having the test. This
contrasts to a greater extent than with concerns
regarding the efficacy of tests and treatments associ-
ated with prostate cancer. MD who had been tested
were more likely to recommend a prostate test for
their patients and had positive attitudes towards
regular prostate cancer testing. Education of doctors
on the issues associated with prostate cancer testing
would be beneficial.
The results indicated that, while a substantial propor-
tion of testing may be done as an investigation of
urinary symptoms among patients, there appears to
be a significant number of tests done on asympto-
matic men. It also appears that many of the tests are
undertaken without men being fully informed of the
potential consequences. Another important finding
was that, while there is basic knowledge about the
issues associated with prostate cancer among men in
the community, this knowledge level appeared insuf-
ficient to make fully informed decisions in relation to
their own tests for prostate cancer.
The benefits of screening are possible and plausible
but, at present, uncertain. Although the benefits are
uncertain, this does not mean that men should not be
allowed to be tested if they understand the issues
involved. It is important that consumers understand
the issues in a way that will permit them to participate
in decisions about whether or not to have a PSA test
or, if symptomatic, in decisions about the way their
condition is managed. Men who simply follow profes-
sional advice could be managed in vastly different
ways, depending on which doctor they consult.
The AHTAC1 and the Urological Society of Austral-
asia do not support population screening unless, and
until, the results of randomized controlled trials show
positive benefits and until resources are in place for
doctors to provide patients with objective information
on the risks and benefits of prostate cancer interven-
tion. Men being offered, or requesting, a PSA test
must be fully informed of the limitations of the tests
currently available and of the possible further diag-
nostic and treatment choices that they may face
should they decide to proceed with an initial test.
This offers a ‘pro-choice’ platform, which allows
doctors to offer testing with balanced information
so that men in the community have a solid basis on
which to accept or reject their doctor’s
recommendations.
Prostate cancer testing is also problematic from the
practitioner’s perspective. There are constraints that
do not allow medical practitioners to spend a great
deal of time with patients explaining the arguments
for and against prostate cancer testing. In addition,
medical practitioners are rightly concerned about the
medico-legal implications if they do not test someone
for prostate cancer and the cancer eventually
develops.
To improve informed choice, the dissemination of
information could be incorporated with population-
based health promotion initiatives that promote a
broad approach to men’s urological health issues.
Information on the issues surrounding prostate
cancer – such as a more realistic understanding of the
low risk of dying from prostate cancer (which is
dependent on age at diagnosis and comorbidities,
stage and grade of tumour), the associated burdens
and the uncertainties linked with prostate cancer
testing and treatments – has been shown to reduce the
desire for PSA screening.13 Information about the
prostate gland, its location, normal function and asso-
ciated disorders, is required. There is a need to
address the issue of the accuracy of prostate cancer
tests, given that men have widely varying beliefs about
their accuracy. There is also a need to challenge the
belief among men in the community that ‘every man
needs to be regularly tested for prostate cancer’ and
to describe what the various prostate cancer tests
actually measure. It is also necessary to resolve confu-
sion about the differences between benign forms of
prostate disease and prostate cancer.
The present study identified a number of major
factors that impact a on man’s decision to have a
prostate cancer test, such as: (i) the attitudes of the
doctor involved, (ii) the impact of media coverage
about the ‘need to be tested’ and (iii) the desire for
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reassurance that prostate cancer was not present,
despite the limitations of current tests. Further
research is needed to identify educational ways of
ensuring that men are making fully informed deci-
sions about prostate cancer testing.
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